Biotech Values

[iwfal]

ARQL

McBio thinks that since they didn't test for c-MET in the Phase III, the trial is suspect.

FWIW I think I am the primary doubter of MARQUEE, because MetMab in their ph ii in a similar (sub)population had a very poor HR. Combine this with the fact that the ARQL was heavily post hoc'd and I have my doubts. But I certainly wouldn't guarantee a negative outcome.